ArticlePDF Available

Tarsitis as an initial manifestation of juvenile spondyloarthropathy

Authors:

Abstract

The aim of this study was to determine the frequency of tarsitis as one of the first symptoms of juvenile spondyloarthropathy (JSpA) and to analyze whether patients with tarsitis at onset differ from those without it. A retrospective chart review was performed, from January 1996 to September 2007, at a paediatric rheumatology unit of a tertiary university hospital. Tarsitis was detected in one-third of the children diagnosed with JSpA. They had fever and received antibiotics due to a suspected infection more frequently than those without tarsitis. Inflammatory low back pain was extremely unusual among these patients. There were some differences between children diagnosed with JSpA initially affected with tarsitis and those without it. Patients with tarsitis as one of the first symptoms were often misdiagnosed as soft tissue infections.
Clinical and Experimental Rheumatology 2009; 27: 691-694.
Paediatric rheumatology
Tarsitis as an initial manifestation of juvenile
spondyloarthropathy
C. Álvarez-Madrid1, R. Merino1, J. De Inocencio2, J. García-Consuegra1
1Paediatric Rheumatology Unit, University Hospital La Paz, Madrid, and 2CS Jazmin and
University Hospital La Paz Foundation for Biomedical Research, Madrid, Spain.
Abstract
Objective
The aim of this study was to determine the frequency of tarsitis as one of the first symptoms of juvenile
spondyloarthropathy (JSpA) and to analyze whether patients with tarsitis at onset differ from those without it.
Methods
A retrospective chart review was performed, from January 1996 to September 2007, at a paediatric rheumatology unit
of a tertiary university hospital.
Results
Tarsitis was detected in one-third of the children diagnosed with JSpA. They had fever and received antibiotics due to a
suspected infection more frequently than those without tarsitis. Inflammatory low back pain was extremely unusual among
these patients.
Conclusion
There were some differences between children diagnosed with JSpA initially affected with tarsitis and those without it.
Patients with tarsitis as one of the first symptoms were often misdiagnosed as soft tissue infections.
Key words
Tarsitis, juvenile spondyloarthropathy, children, tarsus, juvenile idiopathic arthritis
692
PAEDIATRIC RHEUMATOLOGY Tarsitis as a form of juvenile spondyloarthropathy onset / C. Álvarez-Madrid et al.
Carla Álvarez-Madrid, MD
Rosa Merino, MD, PhD
Jaime De Inocencio, MD, PhD
Julia García-Consuegra, MD, PhD
Please address correspondence and
reprint requests to:
Dr R. Merino
Paediatric Rheumatology Unit,
University Hospital La Paz
Po de la Castellana 261
28046 Madrid, Spain.
E-mail: merino.hulp@salud.madrid.org
Received on August 11, 2008; accepted in
revised form on March 4, 2009.
© Copyright CLINICAL AND
EXPERIMENTAL RHEUMATOLOGY 2009.
Competing interests: none declared.
Introduction
Juvenile spondyloarthropathy (JSpA)
often begins as asymmetric, peripheral
arthritis of the lower limbs and enthesi-
tis without axial involvement, in con-
trast to what is observed in adults (1,
2). Tarsitis can appear during the initial
stages of the disease. Tarsitis is defined
as foot inflammation from the ankle to
the metatarsophalangeal joints. Tarsal
involvement related to JSpA was first
described by Burgos-Vargas et al. (3,
4). The acute phase is characterized
by diffuse inflammation of tarsal soft
tissues which can be shown by various
imaging techniques, but it should be
suspected from clinical data. If the in-
flammation persists, the structures may
become damaged leading to fusion of
the tarsal bones. This evolution has
been named ankylosing tarsitis.
The aims of this study were to determine
the frequency of tarsitis as one of the
first symptoms of JSpA and to analyze
whether JSpA patients with tarsitis at
that time differed from those without it.
Patients and methods
A retrospective chart review was per-
formed on all patients diagnosed with
JSpA at the paediatric rheumatology
unit of a tertiary university hospital in
Madrid. According to the Unit Registry
between January 1996 and September
2007 3,995 new cases were evaluated.
Of those, 283 (7%) corresponded to in-
flammatory chronic arthritis being 37
of them diagnosed with JSpA.
The patients were classified according
to the European Spondyloarthropathy
Study Group (ESSG) criteria (5). Sub-
sequently, the enthesitis related arthritis
criteria of the International League of
Associations for Rheumatology (ILAR)
(6) were applied.
Variables collected from the begin-
ning of the symptoms until diagnosis of
JSpA included demographic data, clini-
cal manifestations (tarsitis, arthritis of
other joints, enthesitis, dactylitis, lum-
bar/sacroiliac pain, fever and adminis-
tration of antibiotics due to suspected
infection), laboratory findings (eryth-
rosedimentation rate and HLA-B27 sta-
tus) and imaging studies (radiographs,
bone scans and magnetic resonance im-
aging [MRI]) of the tarsus and pelvis.
Tarsitis was defined as inflammation of
the mid-foot causing pain and limping
documented by a physician. Imaging
techniques were consistent with the
clinical profile. Other etiologies such
as trauma or infections were excluded.
To assess tarsal involvement at diagno-
sis the Spondyloarthropathy Tarsal Ra-
diographic Index (SpA-TRI) was ap-
plied categorizing the lesions in a scale
that ranged from 0 (normal) to 4 (bony
ankylosis) (7).
At the last visit, before September
2007, the number of patients diagnosed
with ankylosing spondilytis (AS) or an-
kylosing tarsitis were recorded.
Statistical analyses were performed us-
ing the SPSS 11.0 package. Descriptive
characteristics of variables were repre-
sented as median, mean and standard
deviation or percentages. Comparisons
between groups were done using the
Mann-Whitney U-test for quantitative
variables, and Chi-square and Fisher’s
exact test for qualitative variables. Dif-
ferences were considered significant at
(p<0.05).
Results
During the study period 37 patients
were diagnosed with JSpA. All chil-
dren fulfilled ESSG criteria. However,
only 32 (86%) were allocated to the
ILAR enthesitis related arthritis catego-
ry. Five patients were excluded: three
because of positive family history of
psoriasis in a first-degree relative; one
of these had disease onset at 17.3 years
of age. Another one, a boy, was diag-
nosed with reactive arthritis. Finally a
girl presented unilateral sacroiliitis and
ankle arthritis with no other criteria.
Thirteen out of 37 (35%) patients had
tarsitis as one of the first symptoms. In
three of them unilateral tarsitis was the
only sign of musculoskeletal involve-
ment. Bilateral tarsitis was found in 4
of the other 10 children. Only one (8%)
of the 13 cases with tarsitis at diagno-
sis had lumbar/sacroiliac pain, in con-
trast to 13 of 24 (54%) without tarsitis.
Fever and antibiotic treatment before
JSpA diagnosis were more frequently
recorded among those who started with
tarsal inflammation. The main clinical
and laboratory characteristics of the
series are reported in Table I. At that
693
PAEDIATRIC RHEUMATOLOGY
Tarsitis as a form of juvenile spondyloarthropathy onset / C. Álvarez-Madrid et al.
time none presented uveitis, and all had
negative antinuclear antibodies.
According to the radiographic index
tarsal involvement at diagnosis was
between grades 0 (normal) and 1 (os-
teopenia) in all cases. Gammagraphic
bone scans of the feet performed in 6
patients showed increased uptake of the
isotope (Fig. 1) and MRI carried out in
5 showed signal enhancement of soft
tissues (Fig. 2). Radiographs of sacro-
iliac joints obtained in 12 of 14 children
with inflammatory lumbar/sacroiliac
pain were normal except for one case.
That patient fulfilled diagnostic criteria
for AS at the first visit and conventional
radiography and MRI confirmed the di-
agnosis. He consulted us 5.3 years after
his symptoms began, had no tarsitis,
and later developed Chron’s disease.
At the last visit, after a mean disease
duration of 3.8±2.6 (0.09-11.3), me-
dian 4.3 years, with no differences be-
tween patients with and without tarsitis
(p=0.22), two children fulfilled criteria
for ankylosing spondylitis, after 5 and 9
years of disease duration, before tumor
necrosis factor antagonists were start-
ed. Neither of them presented tarsitis
as an initial symptom. One was the boy
affected by Chrön’s disease mentioned
above. The other was a boy diagnosed
with JSpA in 1996 when he had back
pain and a normal sacroiliac joints x-
ray. Later in 2005 he complained again
of back pain and his x-ray showed
grade 2 bilateral sacroiliitis. Etanercept
was started and his disease has been in-
active since. None of the patients in the
series had developed ankylosing tarsi-
tis by the end of the study.
Discussion
The ESSG criteria have demonstrated
high sensitivity (83.9%) and specificity
(87.5%) for the diagnosis of JSpA (8).
It is well known that the exclusion sys-
tem of the ILAR criteria does not allow
the classification of all patients (9).
The tendency of JSpA towards males,
with positive HLA-B27 antigen, asym-
metric peripheral arthritis in lower
limbs, enthesitis, and dactylitis has
been previously described (10-12).
The frequency of the spondylarthropa-
thy from the registers of paediatric rheu-
matology clinics is around 10% (13).
In this series, tarsitis was one of the
initial symptoms of JSpA in one-third
(35%) of the patients. According to
other studies up to 71.4% of children
with JSpA developed tarsitis in the first
six months of the disease (14).
At initial stages of JSpA tarsitis should
be suspected by clinical data, and im-
aging techniques should be consistent
with the clinical profile. Tarsal radiog-
raphy helps to exclude osteolitic and
other lesions, whereas bone scan and
Table I. Main characteristics of 37 patients with juvenile spondyloarthropathy at diagnosis,
classified according to the presence or absence of tarsitis.
Values are shown as median, mean ± SD (min-max) and number (percentage)
With tarsitis Without tarsitis p-value
(n=13) (n=24)
Demographic characteristics
Male 9 (69) 17 (71) 0.60
Age at onset (y) 10, 10 ± 4 (3.6-17.3) 9.4, 9.6 ± 2.1 (3.6-14.3) 0.64
Clinical characteristics
Time to diagnosis (y) 0.3, 0.7 ± 0.7 (0.04-2) 0.4, 0.9 ± 1.2 (0.04-5.3) 0.42
Age at diagnosis (y) 10.3, 10.7 ± 4 (3.8-17.7) 10.5, 10.6 ± 2.4 (4-14.7) 0.86
Lower limbs arthritis* 11 (85) 21 (88) 0.58
Asymmetric arthritis 10 (77) 21 (88) 0.34
Enthesitis 7 (54) 11 (46) 0.45
Dactylitis 3 (23) 5 (21) 0.59
Lumbar/sacroiliac pain 1 (8) 13 (54) 0.006
Fever** 6 (46) 4 (17) 0.06
Antibiotic treatment** 6 (46) 1 (4) 0.004
Analytical data
HLA-B27 (+) 11 (85) 21 (88) 0.58
ESR mm/h 56, 56 ± 28 (13-125) 44.5, 45 ± 29 (4-104) 0.26
ESR: Erythrosedimentation rate.
*Predominantly lower limbs arthritis; **Fever and antibiotic treatment before juvenile spondylo-
arthropathy diagnosis.
Fig. 1. Vascular phase of a bone scan demonstrating increased uptake of technetium 99m in soft tis-
sues. It corresponds to a boy diagnosed with juvenile spondyloarthropathy who presented with left
tarsitis as an unique manifestation of the disease.
694
PAEDIATRIC RHEUMATOLOGY Tarsitis as a form of juvenile spondyloarthropathy onset / C. Álvarez-Madrid et al.
MRI reveal the inflammation sites. The
biggest diagnostic challenge is unilater-
al tarsal inflammation and fever with no
other manifestations related to disease.
The present study has significant limi-
tations, as it is a retrospective analysis
with few patients and short disease
duration. It cannot be concluded that
tarsitis is a form of JSpA without sac-
roiliitis nor spondylitis. However, axial
involvement was unfrequent in cases
with tarsitis at disease onset, only 8%,
in contrast to 54% of the children with-
out it. Moreover none of the patients
with tarsitis at diagnosis has developed
axial involvement. However, long-term
studies have shown that JSpA is asso-
ciated with the development of spond-
ylitis and sacroiliitis years after onset
(15), indicating that this is a possible
outcome for those patients.
Despite the limitations of this study
there were some differences between
children diagnosed with JSpA initially
affected with tarsitis and those without
it. In the first group, 46% of the children
had fever and received antibiotic therapy
because of a suspected soft tissue infec-
tion, whereas only 17% of the patients
without tarsitis at onset had fever, and
only 1 (4%) was treated with antibiotics.
This indicates that the diagnosis of JSpA
in children with tarsitis usually requires
the exclusion of an infectious etiology.
This diagnostic dilemma may also be
faced when confronting a patient with
monoarthritis of the knee, ankle or hip,
although the anatomy of those joints al-
lows the clinician to obtain synovial
fluid to make the correct diagnosis.
In summary, patients with JSpA and tar-
sitis as one of the first symptoms were
often misdiagnosed with infections and
the evidence of axial involvement was
low in them.
References
1. MARKS SH, BARNETT M, CALIN A: A case-
control study of juvenile- and adult-onset an-
kylosing spondylitis. J Rheumatol 1982; 9:
739-41.
2. BURGOS-VARGAS R, PETTY RE: Juvenile an-
kylosing spondylitis. Rheum Dis Clin North
Am 1992; 18: 123-42.
3. BURGOS-VARGAS R: Contribuciones de la reu-
matología mexicana al área de las espondiloar-
tropatías. Rev Mex Reumat 2002; 17: 141-52.
4. BURGOS-VARGAS R, PACHECO-TENA C, VÁZ-
QUEZ-MELLADO J: Juvenile-onset spondylo-
arthropathies. Rheum Dis Clin North Am
1997; 23: 569-98.
5. DOUGADOS M, VAN DER LINDEN S, JUHLIN
R et al.: The European Spondylarthropathy
Study Group preliminary criteria for the
classification of spondylarthropathy. Arthri-
tis Rheum 1991; 34: 1218-27.
6. PETTY RE, SOUTHWOOD TR, MANNERS P et
al.: International League of Associations for
Rheumatology Classification of juvenile idio-
pathic arthritis: second revision, Edmonton,
2001. J Rheumatol 2004; 31: 390-2.
7. PACHECO-TENA C, LONDOÑO JD, CAZARÍN-
BARRIENTOS J et al.: Development of a ra-
diographic index to assess the tarsal involve-
ment in patients with spondyloarthropathies.
Ann Rheum Dis 2002; 61: 330-4.
8. KASAPÇOPUR Ö, DEMIRLI N, ÖZDOĞAN H
et al.: Evaluation of classification criteria
for juvenile-onset spondyloarthropathies.
Rheumatol Int 2005; 25: 414-8.
9. MERINO R, DE INOCENCIO J, GARCÍA-
CONSUEGRA J: Evaluation of revised Inter-
national League of Associations for Rheu-
matology Classification Criteria for juvenile
idiopathic arthritis in Spanish children (Ed-
monton 2001). J Rheumatol 2005; 32: 559-
61.
10. ZOCHLING J, BRANDT J, BRAUN J: The cur-
rent concept of spondyloarthritis with special
emphasis on undifferentiated spondyloarthri-
tis. Rheumatology 2005; 44: 1483-91.
11. AGGARWAL A, HISSARIA P, MISRA R: Juven-
ile ankylosing spondylitis – is it the same dis-
ease as adult ankylosing spondylitis? Rheu-
matol Int 2005; 25: 94-6.
12. GENSLER L, DAVIS JC: Recognition and
treatment of juvenile-onset spondyloarthritis.
Curr Opin Rheumatol 2006; 18: 507-11.
13. PRUTKI M, TAMBIC BUKOVAC L, JELUSIC
M, POTOCKI K, KRALIK M, MALCIC I: Retro-
spective study of juvenile spondylarthropa-
thies in Croatia over the last 11 years. Clin
Exp Rheumatol 2008; 26: 693-9.
14. BURGOS-VARGAS R, VÁZQUEZ-MELLADO J:
The early clinical recognition of juvenile-
onset ankylosing spondylitis and its differ-
entiation from juvenile rheumatoid arthritis.
Arthritis Rheum 1995; 38: 835-44.
15. FLATØ B, HOFFMANN-VOLD AM, REIFF A,
FØRRE Ø, LIEN G, VINJE O: Long-term out-
come and prognostic factors in enthesitis-re-
lated arthritis: a case-control study. Arthritis
Rheum 2006; 54: 3573-82.
Fig. 2. MRI of the foot of the same boy with tarsitis represented in Figure 1. The cross-section and
lateral view show gadolinium signal enhancement of soft tissues.
... Despite major functional impact, literature studying foot involvement in ERA is scarce. Tarsitis was seen to be a promi n e n t m a n i f e s t a t i o n i n c a s e s e r i e s o f j u v e n i l e spondyloarthropathy, with 35% of a Brazilian cohort having tarsitis at presentation [13]. Foot disease has not been comprehensively studied in Indian children with ERA, in whom disease tends to be more severe, is diagnosed later, and shows higher prevalence of HLA-B27 than counterparts in the rest of the world [2]. ...
... Our prevalence on clinical assessment is similar to 35% in a study of 37 patients with JSpA [13]. However, in another study, it was found in 29 of 33 active JSpA patients [27]. ...
... Most descriptions of tarsitis in adult and JSpA are from Central and Latin America. This may suggest that the prevalence of midfoot involvement is influenced by geographic and economic factors or infection prevalence, as many cases of tarsitis in a Mexican study had preceding fever [13]. ...
Article
Foot involvement is common in juvenile idiopathic arthritis (JIA) but is often unrecognized and difficult to treat. This study was done to assess clinical and radiological involvement of the feet and its impact on function in Indian children with enthesitis-related arthritis (ERA). We enrolled consecutive children with ERA with disease duration of less than 5 years. All patients underwent clinical examination of the feet and filled the juvenile arthritis foot index (JAFI) questionnaire. Ultrasound (US) of foot joints and entheses and extremity magnetic resonance imaging (MRI) scan of one foot were done. Fifty-five patients (53 boys), with median 14 years and disease duration 1.9 years, were included. Thirty-seven of 46 were HLA-B27-positive. Mean juvenile spondyloarthritis disease activity (JSpADA) index and juvenile idiopathic arthritis disease activity scrore-10 (JADAS10) scores were 4 and 14.25. Forty-six had history of foot pain, 36 had foot involvement on examination (15 ankle, 8 subtalar, 24 midfoot, 10 forefoot, and 21 tendoachilles), and 7 had plantar fascia involvement. On US (N = 55), 16 had ankle involvement and 8 had subtalar involvement, and 19 patients had midfoot arthritis, 24 had tendoachilles enthesitis, and 11 had plantar fasciitis. On MRI (N = 50), 27 had midfoot involvement. Thirty-three had bone edema. Fourteen had midfoot enthesitis and 17 had tenosynovitis. Clinical and US had 82% concordance at the midfoot and 90% at the ankle. MRI had 74% concordance with examination and 72% with US at the midfoot. The median JAFI scores were as follows: total JAFI = 4 (0-11), impairment = 1, activity limitation = 2, and participation restriction = 1. JAFI total and individual domains correlated with JADAS10, JSpADAS, and childhood health assessment questionnaire (CHAQ) but not duration of foot disease. JAFI was higher in children with midfoot arthritis on US. Foot joints and entheses are involved in a substantial proportion of patients with ERA patients and the midfoot is commonly involved. Foot disease produces significant functional limitation.
... Peripheral arthritis is usually asymmetrical and mainly affects lower limbs, with knees and ankles being the most affected joints [35,36]. Tarsitis (intertarsal joints arthritis associated to the phlogosis of the overlying tendons, entheses, and soft tissues) is a typical feature of ERA, and it occurs in up to one third of patients at disease onset [39][40][41]. Tarsitis is characterized by midfoot pain, tenderness, and limitation of movement, which can lead to a forefoot adduction deformity when associated to the first metatarsophalangeal joint arthritis [15]. Unlike other JIA subtypes, hip involvement is common in ERA (20-40%) [35,36] and an isolated hip arthritis may also be the sole manifestation at disease onset [41,42]. ...
Article
Full-text available
Enthesitis-related arthritis (ERA) represents 5–30% of all cases of juvenile idiopathic arthritis (JIA) and belongs to the spectrum of the disorders included in the group of juvenile spondyloarthritis. In the last decade, there have been considerable advances in the classification, diagnosis, monitoring, and treatment of ERA. New provisional criteria for ERA have been recently proposed by the Paediatric Rheumatology INternational Trials Organisation, as part of a wider revision of the International League of Associations for Rheumatology criteria for JIA. The increased use of magnetic resonance imaging has shown that a high proportion of patients with ERA present a subclinical axial disease. Diverse instruments can be used to assess the disease activity of ERA. The therapeutic recommendations for ERA are comparable to those applied to other non-systemic JIA categories, unless axial disease and/or enthesitis are present. In such cases, the early use of a TNF-alpha inhibitor is recommended. Novel treatment agents are promising, including IL-17/IL-23 or JAK/STAT pathways blockers.
... Tarsal involvement is characteristic for the initial stages of JIA and may be recognized in up to 1/3 of cases (23,24) . Our results are in conformance with these findings. ...
Article
Full-text available
Aim To evaluate the spectrum of inflammatory features in foot joints which may be detected on routinely performed ultrasound (US) and magnetic resonance imaging (MRI) in children newly diagnosed with juvenile idiopathic arthritis (JIA). Material and methods Two groups of children hospitalized in a reference center for rheumatology, newly diagnosed with JIA and suspected of foot involvement in the course of JIA were included in this retrospective study. In the first group of 47 patients aged 1–18 years, the imaging was restricted to US. The second group of 22 patients aged 5–18 years underwent only non-contrast MRI of the foot. Results The most frequent pathologies seen on US included effusion and synovial thickening in the first metatarsophalangeal joint (MTP1), followed by the tibiotalar joint. Synovial hyperemia on color Doppler US images was present most frequently in the Chopart and midtarsal joints (64%; 7/11 cases), followed by the tibiotalar joint (45%; 5/11), and MTP2–5 joint synovitis (40%; 4/10). Grade 3 hyperemia was present only in four cases; grades 1 and 2 were detected in the majority of cases. On MRI, bone marrow edema was the most frequent pathology, found mostly in the calcaneus (45%; 10/22 cases), while alterations of the forefoot were rare. No cases of bursitis, enthesitis, cysts, erosions or ankylosis were diagnosed in either of the analyzed groups. Conclusions Routine US of the foot is recommended for early detection of its involvement in JIA in daily clinical practice. Although MRI can identify features of various JIA stages, it is particularly useful for the detection of bone marrow alterations.
... There was no correlation with sacroiliitis or HLA-B27. Similar early prevalence was described in a Spanish cohort, where 35% had tarsitis at presentation (47). In this series, the children with tarsitis were much less likely to present with axial pain (8 vs. 54%) or develop axial involvement, and were often initially misdiagnosed with infection. ...
Article
Full-text available
Some studies have suggested children with juvenile onset spondyloarthritis (JoSpA) have a relatively poor outcome compared to other juvenile idiopathic arthritis (JIA) categories, in regards to functional status and failure to attain remission. Thus, in the interest of earlier recognition and risk stratification, awareness of the unique characteristics of this group is critical. Herein, we review the clinical burden of disease, prognostic indicators and outcomes in JoSpA. Of note, although children exhibit less axial disease at onset compared to adults with spondyloarthritis (SpA), 34–62% have magnetic resonance imaging (MRI) evidence for active inflammation in the absence of reported back pain. Furthermore, some studies have reported that more than half of children with “enthesitis related arthritis” (ERA) develop axial disease within 5 years of diagnosis. Axial disease, and more specifically sacroiliitis, portends continued active disease. The advent of TNF inhibitors has promised to be a “game changer,” given their relatively high efficacy for enthesitis and axial disease. However, the real world experience in various cohorts since the introduction of more widespread TNF inhibitor usage, in which greater than a third still have persistently active disease, suggests there is still work to be done in developing new therapies and improving the outlook for JoSpA.
... Because the small joints of the hands are rarely affected, disease of these joints is less likely to be ERA [34]. Tarsitis, manifested as pain and tenderness in the midfoot, is more common than other subtypes of JIA [42,43]. ...
... Upala enteza, tetivnih ovojnica, sinovije te sinovijalnih burza u srednjem dijelu stopala od skočnog do metatarzofalangealnih zglobova naziva se ankilozantni tarzitis (AT) i može biti jedan od prvih simptoma jSpA. 30,31 Zahvaćenost stopala klinički se manifestira bolnošću koja se javlja prilikom stajanja i hodanja, otokom stopala te bolnošću prilikom pritiska na mjesta na kojima se tetive i ligamenti spajaju s kosti. U kasnijem tijeku bolesti entezitis varira od rijetkih epizoda aktivne upale jedne ili više enteza do čestih vraćanja upale na mnogim mjestima, osobito na stopalu. ...
Article
Full-text available
Juvenile spondyloartrhritis is a group of multifactorial diseases in which a disturbed interplay occurs between the immune system and environmental factors on a predisposing genetic background, which leads to inflammation and structural damage of the target tissue. First symptoms of jSpA rarely involve the spine, while asymmetrical oligoarthritis of lower extremities, dactylitis, and peripheral enthesitis are much more common. There are many classification criteria for jSpA, but the majority of pediatric rheumatologists currently use the International League Against Rheumatism (ILAR) criteria according to which most patients with jSpA are classified into the enthesitis-related arthritis group of juvenile idiopathic arthritis. To meet these criteria, a patient should have arthritis and/or enthesitis, with two or more symptoms such as sacroiliac joint tenderness and/or inflammatory back pain, HLAB27 genotype, HLA B27 genotype-associated disease in a first- or second-degree relative, uveitis, and male sex with eight or more years of age. Therefore, diagnosis is most oft en made only based on clinical examination and medical history. Anti- nuclear antibodies (ANA), rheumatoid factor (RF), and HLA testing with B27, B7, and DR4 alleles are preferred. Since subclinical gut inflammation is present in many patients, it is recommended to check fecal calprotectin levels. In patients with signs of peripheral enthesitis it is warranted to perform power Doppler musculoskeletal ultrasound (PDUS), and in patients with signs of axial involvement radiographic and contrast-enhanced magnetic resonance imaging. Most patients are treated with nonsteroidal anti-inflammatory drugs (NSAIDs) and physical therapy, while in refractory cases with peripheral disease synthetic disease- modifying antirheumatic drugs (DMARDs), such as sulfasalazine, are used. In patients with axial involvement, biological DMARDs such as adalimumab, infliximab, and etanercept are obligatory. Although a number of studies gave us a good insight into the disease pathogenesis, the response to treatment and prognosis are still difficult to predict.
... of children with juvenile SpA, a condition that encompasses most children with ERA, have tarsitis at disease onset [16]. ...
Article
Full-text available
Enthesitis-related arthritis (ERA) is phenotypically distinct from the other categories of juvenile idiopathic arthritis (JIA). Therefore, patients with ERA warrant distinct pharmacological treatments tailored to their disease process. The advent of biologic disease-modifying agents (biologics) has revolutionized the treatment of ERA. Biologics are drugs that are genetically engineered from a living organism (such as a virus, gene, or protein) to modify signaling along the inflammatory pathway and thereby modulate the immune system. There has been movement over the last decade to categorize and treat patients with spondyloarthritis on the basis of axial disease since axial involvement warrants treatment with a biologic, in particular, a tumor necrosis factor alpha (TNF-α) blocker. To help identify ERA patients correctly for research purposes, the use of ultrasound with Doppler (USD) and/or whole-body magnetic resonance imaging (MRI) is being increasingly used; their role in clinical practice, however, is still undetermined. We strongly recommend that MRI of the pelvis be performed for any ERA patient in whom axial disease is suspected as its presence may influence the medication regimen, specifically initiation of a biologic. The recent development of a spondyloarthritis (including ERA)-specific disease activity tool called the Juvenile Spondyloarthritis Disease Activity Score (JSpADA) will hopefully allow pediatric rheumatologists to better monitor disease activity over time. Over the last decade, there has been a plethora of research to help advance our understanding of the etiopathogenesis of spondyloarthritis. Future promising treatments for ERA are evidenced by research implicating the role of the IL-12/23 and IL-17 axis in spondyloarthritis. Investigations examining the microbiome will further elucidate the interactions between genetics and the environment that lead to the development of ERA. With more randomized therapeutic trials and more microbiome and genetics-related research, we will likely see the development of targeted therapies for the treatment of ERA in the near future.
Article
Full-text available
Juvenile spondyloarthropathies (JSpA) are defined as a heterogeneous group of diseases that start before the age of 16, which is associated with peripheral joint (especially large joints of the lower limbs) and axial skeletal (spine and sacroiliac joint) involvement, enthesitis, and human leukocyte antigen (HLA) B27 positivity. Juvenile spondyloarthropathies mainly cover juvenile ankylosing spondylitis (JAS), psoriatic arthritis, reactive arthritis, inflammatory bowel disease-associated arthritis, seronegative enthesopathy, arthropathy syndrome (SEA), and enthesitis-associated arthritis. Symptoms associated with spondyloarthropathies are enthesitis, inflammatory low back pain, dactylitis, nail changes, psoriasis, acute anterior uveitis, and inflammatory bowel disease-related symptoms. In JSpA, axial involvement is rarely seen in the early stages of the disease, in contrast to adult patients with ankylosing spondylitis (AS). The disease usually begins as asymmetric oligoarthritis of lower extremities in children, and axial skeletal involvement can occur in the course of the disease. Although the debate on the classification of juvenile spondyloarthropathies continues due to its initial nonspecific findings and the heterogeneity of the disease phenotype, the International League of Associations Rheumatology (ILAR) classification criteria are the most commonly used pediatric criteria. In that set of criteria, patients with JSpA are mainly classified under enthesitis-related arthritis or psoriatic arthritis group. Since juvenile spondyloarthropathies can cause severe loss of function and long-term sequelae, the main goal in treatment should be suppression of inflammation as early as possible and prevent sequelae.
Article
Full-text available
To determine the frequency of juvenile spondylarthropathies (JSpA) among other rheumatic diseases in a pediatric clinic population in an 11-year period in Croatia and to review their clinical, epidemiological, radiographic and laboratory. Of the 1264 patients with rheumatic diseases seen at a pediatric rheumatology center, 103 (8.2%) were diagnosed as having JSpA (56 boys, mean age 13.1 years, range 4.4-17.8 years), following the strict criteria of the European Spondylarthropathy Study Group. Medical history, clinical laboratory and imaging data of the 103 patients with JSpA were analyzed. Eighty-two (79.6%) patients had undifferentiated spondylarthropathy, 6 (5.8%) patients had reactive arthritis/Reiter's disease, 6 (5.8%) had arthritis associated with inflammatory bowel disease, 5 (4.9%) had psoriatic arthritis, and only 4 (3.9%) patients had ankylosing spondylitis. The most common symptoms at the disease onset in patients with JSpA were peripheral and axial arthritis, followed by enthesitis. A significant increase in the number of patients with axial arthritis, peripheral arthritis, ocular symptoms and enthesitis was found during mean period of follow-up of 6.45 years. HLA-B27 was present in 78 (75.7%) patients. In our hospital population the frequency of JSpA among other rheumatic disease was 8.2%. The disease was equally distributed among male and female patients, with onset around the age of 13 years. Most of the patients were diagnosed with undifferentiated spondylarthropathy.
Article
Full-text available
To develop and test an index to evaluate the radiographic changes that occur in the tarsus and adjacent areas of the foot in patients with spondyloarthropathies (SpA). The spondyloarthropathy tarsal radiographic index (SpA-TRI) was developed in three consecutive steps: (a) detection of descriptors after reviewing 70 radiographic files; (b) descriptor gradation and subsequent modifications performed by a consensus committee, and (c) interobserver variability assessed by three blinded and independent observers on 272 radiographs: anteroposterior 118, lateral 90, oblique 64 from 121 patients with SpA, and intraobserver variability on 75 radiographs from 25 patients with SpA. Statistical analysis included percentage of agreement and kappa test. SpA-TRI score ranges from 0 to 4 (0=normal; 1=osteopenia or suspicious findings; 2=definite joint space narrowing, bony erosion(s), periosteal whiskering, or enthesophyte(s) in the plantar fascia or Achilleal tendon attachments; 3=para-articular enthesophyte(s); 4=bony ankylosis (joint space fusion or complete bridging)). Complete agreement for every evaluation was >40%, and discordance >1 grade was <15%. The kappa scores among the three observers were acceptable for all the single projections: oblique (0.52, 0.36, 0.35), lateral (0.50, 0.42, 0.56), and anteroposterior (0.40, 0.41, 0.21) views. The combination of lateral and oblique views achieved the highest concordance rates (0.72, 0.33, 0.66), surpassing that of the three projections altogether (0.34, 0.58, 0.37). In every case the concordance was comparable with that of sacroiliac joints (0.47, 0.41, 0.34); intraobserver concordance showed a similar trend. The SpA-TRI is an index that includes the most prominent features of tarsal disease and adjacent areas of the foot in SpA and grades them accordingly, it has an adequate reproducibility, and is suitable for use with two or more projections, preferably the combination of oblique and lateral.
Article
We are beginning to understand the clinical nature of JAS, its relationship with other SSA, and factors involved in its pathogenesis. Clinical data may now allow early recognition of JAS through the identification of children with the SEA syndrome or chronic arthritis associated with the HLA-B27. Comparative clinical studies of the prevalence of the disease and the role of irnmunogenetic, racial and environmental factors are needed. It may be necessary to review current criteria for the diagnosis of JRA and to develop similar criteria for the diagnosis of AS in childhood and adolescence.
Article
Classification criteria for most of the disorders belonging to the spondylarthropathy group already exist. However, the spectrum of spondylarthropathy is wider than the sum of these disorders suggests. Sero-negative oligoarthritis, dactylitis or polyarthritis of the lower extremities, heel pain due to enthesitis, and other undifferentiated cases of spondylarthropathy have been ignored in epidemiologic studies because of the inadequacy of existing criteria. In order to define classification criteria that also encompass patients with undifferentiated spondylarthropathy, we studied 403 patients with all forms of spondylarthropathy and 674 control patients with other rheumatic diseases. The diagnoses were based on the local clinical expert's opinion. The 403 patients included 168 with ankylosing spondylitis, 68 with psoriatic arthritis, 41 with reactive arthritis, 17 with inflammatory bowel disease and arthritis, and 109 with unclassified spondylarthropathy. Based on statiscal analysis and clinical reasoning, we propose the following classification criteria for spondylarthropathy inflammatory spinal pain or synovitis (asymmetric or predominantly in the lower limbs), together with at least 1 of the following: positive family history, psoriasis inflammatory bowel disease, urethritis, or acute diarrhea, alternating buttock pain, enthesopathy, or sacroiliitis as determined from radiography of the pelvic region. These criteria resulted in a sensitivity of 87% and a specificity of 87%. The proposed classification criteria are easy to apply in clinical practice and performed well in all 7 participating centers. However, we regard them as preliminary until they have been further evaluated in other settings.
Article
We are beginning to understand the clinical nature of JAS, its relationship with other SSA, and factors involved in its pathogenesis. Clinical data may now allow early recognition of JAS through the identification of children with the SEA syndrome or chronic arthritis associated with the HLA-B27. Comparative clinical studies of the prevalence of the disease and the role of immunogenetic, racial and environmental factors are needed. It may be necessary to review current criteria for the diagnosis of JRA and to develop similar criteria for the diagnosis of AS in childhood and adolescence.
Article
One hundred and forty-two consecutive patients with ankylosing spondylitis were evaluated. The twenty-two with juvenile-onset disease were selected and compared with twenty-two adult-onset patients, matched for sex and disease duration. Peripheral arthropathy occurred in 17 children and 4 adults (p<0.01). Peripheral arthritis proeceeded low back symptoms in 13 children and 2 adults (p<0.01); it persisted in 7 children and no adults (p<0.05). Hip disease affected 11 children and 4 adults. The explanation for these differences is unclear but may suggest undefined, prepubertal factors affecting the course of juvenile-onset disease.
Article
To determine which early clinical data differentiate juvenile-onset ankylosing spondylitis (AS) from juvenile rheumatoid arthritis (JRA). Medical records of 35 patients with juvenile-onset AS and 75 with JRA (excluding type II pauciarticular JRA), all of whom had disease onset at age < or = 16 years, disease duration of < or = 2 1/2 years at the initial visit to the rheumatology clinic, and followup of > or = 10 years, were analyzed retrospectively with regard to features of disease found 6 months, 12 months, and 10 years after onset. At 6 months, various features appeared more frequently in the juvenile-onset AS group than in the JRA group, i.e., pauciarthritis (54.3% versus 30.7%; P = 0.03, odds ratio [OR] = 2.7), enthesopathy (82.9% versus 0%; P < 0.0001, OR = 321.4), tarsal disease (71.4% versus 1.3%; P < 0.0001, OR = 185.0), and lumbar/sacroiliac symptoms (11.4% versus 0%; P = 0.02, OR = 11.9). At 12 months, the features found more frequently among juvenile-onset AS patients than JRA patients were enthesopathy (88.6% versus 4.0%; P < 0.0001, OR = 186.0), tarsal disease (85.7% versus 10.7%; P < 0.0001, OR = 50.3), and knee disease (100.0% versus 82.7%; P = 0.04, OR = 8.0). Involvement of the upper extremities (especially the hands) was found in significantly fewer juvenile-onset AS patients compared with the JRA group. Definite involvement of the spine and sacroiliitis in juvenile-onset AS occurred after a mean +/- SD of 7.3 +/- 2.0 years. Regardless of axial disease, enthesopathy and tarsal disease in children who have arthritis of the lower, but not of the upper extremities differentiate juvenile-onset AS from JRA within 1 year of symptoms. The discriminative value of these parameters approaches that of axial disease (the gold standard) throughout the followup period.
Article
This article discusses the clinical spectrum and characteristics of juvenile-onset spondyloarthropathies and includes a review of the demographic, clinical, radiographic (and other imaging techniques), and laboratory data of conditions, syndromes, and diseases making up this group. The pathogenic role of several factors in the context of adult-onset patients, but also in regards to studies already performed in juvenile-onset patients, is discussed.
Article
Juvenile and adult forms of ankylosing spondylitis (AS) have been shown to have different clinical presentation and outcome in Caucasians. We did this retrospective analysis to see if similar differences exist in the Indian population. Case records of 210 Indian patients diagnosed with AS according to modified New York criteria were reviewed. Data were collected regarding age of onset, clinical features, drug treatment, and outcome at last follow-up. Patients with onset before 17 years of age were classified as having juvenile AS (JAS) and the rest with adult AS (AAS). There were 150 patients with AAS and 60 with JAS. The latter had higher male preponderance, more frequent onset with peripheral arthritis, and greater involvement of hip and knee joints. Valvular dysfunction was seen only in patients with JAS. In this group of subjects, juvenile AS had onset more often with oligoarthritis and enthesitis than with spinal disease. Hip and knee joint involvement was more common in JAS than AAS.